Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sublingual immunotherapy in allergic rhinoconjunctivitis
PACTR201901529431463Phase 4Completed
- Sponsor
- Zagazig University Faculty of Medicine
- Start
- Feb 2017
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of house dust mite allergen extract in allergic rhinoconjunctivitis (ARC) (2 arms), sponsored by Zagazig University Faculty of Medicine. Primary endpoint: Improvement of patients quality of life. Started Feb 2017; status: completed.
02
Drugs
house dust mite allergen extract
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on PACTR201901529431463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201901529431463.